This timeline tracks the regulatory approval process for lenacapavir (LEN) for HIV prevention from late 2024 through early 2026. Key milestones include FDA Priority Review status, FDA approval in June 2025, expected subsequent approvals from European regulators and WHO, and Global Fund and PEPFAR commitment to roll out LEN to three million people over the next three years.

Topics:

Tracking and Translating the Field